NAB:ASX

National Australia Bank Limited

Data as of 2026-03-10 - not real-time

A$46.95

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

National Australia Bank is trading at $46.95, just below its 20‑day SMA of 47.26 but comfortably above the 50‑day SMA of 44.40, indicating short‑term bullish momentum despite a bearish MACD histogram. Revenue growth of 8.7% and a trailing EPS of 2.21 have driven a recent profit beat that pushed the share price to a fresh record of $47.96, reinforcing confidence in the bank’s earnings power. The RSI of 54.2 suggests the stock is neither overbought nor oversold, while the 30‑day volatility of 25% and low beta of 0.37 point to a relatively defensive profile within the financial sector. However, the forward P/E of 18.5 and current P/E of 21.2 sit above the industry average of 17.4, implying a valuation premium that may limit upside. The dividend yield of 3.69% with a payout ratio near 77% remains attractive, but the upside/downside estimate of –8.4% and a support level at 44.21 signal limited near‑term price appreciation.
The broader market sentiment is extremely greedy (Fear‑Greed Index 75.9), and recent news of a CFO transition adds a layer of governance uncertainty, though the bank’s strong capital base and low liquidity risk mitigate this. Given the blend of solid earnings, attractive yield, and modest valuation stretch, the stock appears fairly positioned for hold in the medium to long term, with a slight bias toward buying on any pull‑back toward support.

Trading Recommendations

Short Term

< 1 year
buy
Conviction: 7/10

Key Factors

  • Quarterly profit beat and record high price rally
  • Price above 20‑day SMA indicating bullish momentum
  • Strong dividend yield enhancing total return

Medium Term

1–3 years
hold
Conviction: 6/10

Key Factors

  • Valuation premium relative to industry peers
  • Steady revenue and earnings growth
  • Moderate regulatory and governance risk

Long Term

> 3 years
hold
Conviction: 5/10

Key Factors

  • Sustainable dividend payout supporting income investors
  • Low beta and defensive defensive profile
  • Limited upside due to elevated valuation multiple

Key Metrics & Analysis

Financial Health

Revenue Growth8.70%
Profit Margin34.46%
P/E Ratio21.2
P/B Ratio2.3
Industry P/E17.4

Technical Analysis

TrendBullish
RSI54.2
SupportA$44.21
ResistanceA$49.45
MA 20A$47.26
MA 50A$44.40
MA 200A$41.96
MACDBearish
VolumeDecreasing
Fear & Greed Index75.89

Valuation

Target PriceA$43.01
Upside/Downside-8.40%
GradeOvervalued
TypeBlend
Dividend Yield3.69%

Risk Assessment

Beta0.37
Volatility25.30%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.